Neurocrine Biosciences Statistics

Total Valuation

Neurocrine Biosciences has a market cap or net worth of GBP 12.37 billion. The enterprise value is 11.61 billion.

Market Cap	12.37B
Enterprise Value	11.61B

Important Dates

The next estimated earnings date is Friday, February 7, 2025.

Earnings Date	Feb 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+2.91%
Shares Change (QoQ)	+0.38%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	100.08M

Valuation Ratios

The trailing PE ratio is 42.95.

PE Ratio	42.95
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	6.19
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 21.86, with an EV/FCF ratio of 35.35.

EV / Earnings	40.32
EV / Sales	6.43
EV / EBITDA	21.86
EV / EBIT	23.96
EV / FCF	35.35

Financial Position

The company has a current ratio of 4.37, with a Debt / Equity ratio of 0.11.

Current Ratio	4.37
Quick Ratio	3.98
Debt / Equity	0.11
Debt / EBITDA	0.43
Debt / FCF	0.65
Interest Coverage	130.93

Financial Efficiency

Return on equity (ROE) is 16.35% and return on invested capital (ROIC) is 14.26%.

Return on Equity (ROE)	16.35%
Return on Assets (ROA)	11.79%
Return on Invested Capital (ROIC)	14.26%
Return on Capital Employed (ROCE)	19.40%
Revenue Per Employee	984,325
Profits Per Employee	169,365
Employee Count	1,400
Asset Turnover	0.70
Inventory Turnover	19.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +7.55% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+7.55%
50-Day Moving Average	135.82
200-Day Moving Average	133.65
Relative Strength Index (RSI)	76.09
Average Volume (20 Days)	1,350

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.30

Income Statement

In the last 12 months, Neurocrine Biosciences had revenue of GBP 1.67 billion and earned 287.92 million in profits. Earnings per share was 2.78.

Revenue	1.67B
Gross Profit	1.14B
Operating Income	449.38M
Pretax Income	389.17M
Net Income	287.92M
EBITDA	468.55M
EBIT	449.38M
Earnings Per Share (EPS)	2.78

Full Income Statement

Balance Sheet

The company has 916.21 million in cash and 213.53 million in debt, giving a net cash position of 702.68 million.

Cash & Cash Equivalents	916.21M
Total Debt	213.53M
Net Cash	702.68M
Net Cash Per Share	n/a
Equity (Book Value)	2.03B
Book Value Per Share	20.05
Working Capital	1.08B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 355.44 million and capital expenditures -27.08 million, giving a free cash flow of 328.36 million.

Operating Cash Flow	355.44M
Capital Expenditures	-27.08M
Free Cash Flow	328.36M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 68.07%, with operating and profit margins of 26.85% and 17.21%.

Gross Margin	68.07%
Operating Margin	26.85%
Pretax Margin	23.26%
Profit Margin	17.21%
EBITDA Margin	28.00%
EBIT Margin	26.85%
FCF Margin	19.62%

Dividends & Yields

Neurocrine Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.91%
Shareholder Yield	-2.91%
Earnings Yield	2.33%
FCF Yield	2.66%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Neurocrine Biosciences has an Altman Z-Score of 11.35.

Altman Z-Score	11.35
Piotroski F-Score	n/a